A new University of Toronto-led study has discovered a possible biomarker linked to multiple sclerosis (MS) disease progression that could help identify patients most likely to benefit from new drugs.

Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...

The FDA approved Scinopharm's glatiramer acetate injection, a generic version of Copaxone, to treat multiple sclerosis.

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

As a result, you may be surprised by the changes in symptoms and treatment possibilities available to you once you’re diagnosed with SPMS. Keep reading to learn what to expect if you were recently ...

ETHealthworld.com brings latest multiple sclerosis news, views and updates from all top sources for the Indian Health industry.

- The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide - - In a pivotal PPMS study ...

New MS treatments target myelin repair, neuroprotection, and CNS-resident immune cells, offering hope for progressive forms of the disease. Bruton tyrosine kinase inhibitors (BTKis) like tolebrutinib ...

Sanofi provides update on tolebrutinib regulatory submission in non-relapsing secondary progressive multiple sclerosis Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a ...

Paris, December 24, 2025. The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) for the new drug application of tolebrutinib to treat non-relapsing secondary ...